{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:13:49Z","timestamp":1773317629671,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/bf03404377","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T16:53:39Z","timestamp":1568307219000},"page":"220-225","source":"Crossref","is-referenced-by-count":31,"title":["Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Qu\u00e9bec, Canada"],"prefix":"10.17269","volume":"101","author":[{"given":"Arthi","family":"Vijayaraghavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly B.","family":"Efrusy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Mayrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Santas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Goggin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"BF03404377_CR1","volume-title":"Cervical Cancer Screening in Canada: 1998 Surveillance Report","author":"Public Health Agency of Canada.","year":"2002","unstructured":"Public Health Agency of Canada. Cervical Cancer Screening in Canada: 1998 Surveillance Report. Ottawa, ON: Public Works and Government Services Canada, 2002. Available at: \n                    https:\/\/doi.org\/www.phac-aspc.gc.ca\n                    \n                  \/publicat\/ccsicdccuac\/index-eng.php (Accessed October 14, 2008)."},{"key":"BF03404377_CR2","volume-title":"Canadian Cancer Statistics 2008","author":"Canadian Cancer Society\/National Cancer Institute of Canada.","year":"2008","unstructured":"Canadian Cancer Society\/National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto, ON: Canadian Cancer Society\/National Cancer Institute of Canada, 2008. Available at: \n                    https:\/\/doi.org\/www.cancer.ca\n                    \n                  \/statistics (Accessed September 18, 2008)."},{"issue":"16","key":"BF03404377_CR3","volume":"357","year":"2007","unstructured":"Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. for the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579\u201388.","journal-title":"N Engl J Med"},{"issue":"7","key":"BF03404377_CR4","volume":"100","year":"2008","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. on behalf of the New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100(7):492\u2013501.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"BF03404377_CR5","volume":"44","year":"2008","unstructured":"Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44(4):565\u201371.","journal-title":"Eur J Cancer"},{"key":"BF03404377_CR6","doi-asserted-by":"crossref","unstructured":"Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. for the Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 2008;337:a1754.","DOI":"10.1136\/bmj.a1754"},{"issue":"Suppl10","key":"BF03404377_CR7","volume":"26","year":"2008","unstructured":"Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl 10):K29\u2013K41.","journal-title":"Vaccine"},{"issue":"2","key":"BF03404377_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2008.08.030","volume":"112","author":"A Vijayaraghavan","year":"2008","unstructured":"Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol 2008;112(2):377\u201383.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"BF03404377_CR9","volume":"119","year":"2006","unstructured":"Mayrand MH, Duarte-Franco E, Coutl\u00e9e F, Rodrigues I, Walter SD, Ratnam S, et al. for the CCCaST Group. Randomized controlled trial of human papillo-mavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). Int J Cancer 2006;119(3):615\u201323.","journal-title":"Int J Cancer"},{"issue":"6","key":"BF03404377_CR10","volume":"12","year":"2003","unstructured":"Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12(6):485\u201390.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"BF03404377_CR11","first-page":"19","volume":"19","author":"JA Snider","year":"1998","unstructured":"Snider JA, Beauvais JE. Pap smear utilization in Canada: Estimates after adjusting the eligible population for hysterectomy status. Chron Dis Can 1998;19(1):19\u201324.","journal-title":"Chron Dis Can"},{"issue":"7","key":"BF03404377_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervico-vaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"BF03404377_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/jnci\/dji162","volume":"97","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst 2005;97(12):888\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"BF03404377_CR14","volume":"285","year":"2001","unstructured":"Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraep-ithelial lesion development in young females. JAMA 2001;285(23):2995\u20133002.","journal-title":"JAMA"},{"issue":"12","key":"BF03404377_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","volume":"151","author":"ER Myers","year":"2000","unstructured":"Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151(12):1158\u201371.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"BF03404377_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3201\/eid0901.020168","volume":"9","author":"GD Sanders","year":"2003","unstructured":"Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9(1):37\u201348.","journal-title":"Emerg Infect Dis"},{"key":"BF03404377_CR17","volume-title":"Survival Reports, v3.0","author":"National Cancer Database NCDB, Commission on Cancer, ACoS\/ACS.","year":"2007","unstructured":"National Cancer Database (NCDB), Commission on Cancer, ACoS\/ACS. Survival Reports, v3.0. January 25, 2007. Available at: \n                    https:\/\/doi.org\/web.facs.org\n                    \n                  \/ncdbbmr\/sas6\/surv\/GRAPHS\/OY97S38XaT00000B.html (Accessed January 30, 2008)."},{"key":"BF03404377_CR18","volume-title":"Estimates of healthy life expectancy for 191 countries in the year 2000: Methods and results","year":"2000","unstructured":"Mathers CD, Murray CJL, Lopez AD, Salomon JA, Sadana R, Tandon A, et al. Estimates of healthy life expectancy for 191 countries in the year 2000: Methods and results. GPE Discussion Paper No. 38, Geneva, WHO, 2000. Available at: \n                    https:\/\/doi.org\/www.who.int\n                    \n                  \/choice\/demography\/health_valuations\/en\/index.html (Accessed June 2008)."},{"key":"BF03404377_CR19","unstructured":"Statistics Canada, Canadian Community Health Survey (CCHS 3.1), 2005 (CANSIM table 105-0442). Available at: \n                    https:\/\/doi.org\/www.statcan.gc.ca\n                    \n                  \/pub\/82-221x\/2008001\/tmap-tcarte\/dt-td\/aces3ps-eng.htm (Accessed June 2008)."},{"key":"BF03404377_CR20","volume-title":"2007 Annual Report","author":"C A C C S Program BC","year":"2008","unstructured":"BC Cancer Agency Cervical Cancer Screening Program. 2007 Annual Report. Vancouver, BC: Cervical Cancer Screening Program, January 2008. Available at: \n                    https:\/\/doi.org\/www.bccancer.bc.ca\n                    \n                  \/PPI\/Screening\/Cervical (Accessed June 2008)."},{"key":"BF03404377_CR21","volume-title":"Manuel des m\u00e9decins omniprati-ciens. Services de laboratoire en \u00e9tablissement","author":"d l m d Qu\u00e9bec R\u00e9gie","year":"2005","unstructured":"R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec. Manuel des m\u00e9decins omniprati-ciens. Services de laboratoire en \u00e9tablissement. Mise \u00e0 jour: 15 juin 2005. Available at: \n                    https:\/\/doi.org\/www.ramq.gouv.qc.ca\n                    \n                  \/fr\/professionnels\/medomni\/manuel\/man120.shtml (Accessed December 18, 2008)."},{"key":"BF03404377_CR22","volume-title":"Ontario guide to case costing","author":"Ontario Ministry of HealthLong-Term Care.","year":"2006","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario guide to case costing. Updated September 2006. Available at: \n                    https:\/\/doi.org\/www.occp.com\n                    \n                  \/ (Accessed January 2008)."},{"issue":"6","key":"BF03404377_CR23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0002-9378(03)00418-6","volume":"188","author":"ASCUS-LSIL Triage Study ALTS","year":"2003","unstructured":"ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188(6):1383\u201392.","journal-title":"Am J Obstet Gynecol"},{"key":"BF03404377_CR24","volume-title":"NCCN clinical practice guidelines in oncology: Cervical cancer","author":"National Comprehensive Cancer Network NCCN.","year":"2008","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Cervical cancer. V.1.2008. National Comprehensive Cancer Network, Inc., 2007. Available at: \n                    https:\/\/doi.org\/www.nccn.org\n                    \n                  \/professionals\/physician_gls\/f_guidelines.asp (Accessed December 18, 2008)."},{"key":"BF03404377_CR25","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","author":"Canadian Agency for DrugsTechnologies in Health CADTH.","year":"2006","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd Edition. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006. Available at: \n                    https:\/\/doi.org\/www.cadth.ca\n                    \n                  \/media\/pdf\/186_EconomicGuidelines_e.pdf (Accessed September 25, 2008).","edition":"3rd"},{"issue":"7","key":"BF03404377_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/aje\/kwk059","volume":"165","author":"N Velde Van de","year":"2007","unstructured":"Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165(7):762\u201375.","journal-title":"Am J Epidemiol"},{"key":"BF03404377_CR27","volume-title":"Macroeconomics and health: Investing in health for economic development: Report of the Commission on Macroeconomics and Health","author":"World Health Organization.","year":"2001","unstructured":"World Health Organization. Macroeconomics and health: Investing in health for economic development: Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001."},{"issue":"5","key":"BF03404377_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/jnci\/djn019","volume":"100","author":"JD Goldhaber-Fiebert","year":"2008","unstructured":"Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100(5):308\u201320.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"BF03404377_CR29","volume":"287","year":"2002","unstructured":"Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287(18):2372\u201381.","journal-title":"JAMA"},{"issue":"Suppl1","key":"BF03404377_CR30","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1016\/j.vaccine.2007.11.069","volume":"26","author":"EL Franco","year":"2008","unstructured":"Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(Suppl 1):A16\u2013A23.","journal-title":"Vaccine"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03404377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03404377\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03404377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T12:45:09Z","timestamp":1568378709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03404377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BF03404377"],"URL":"https:\/\/doi.org\/10.1007\/bf03404377","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}